Rivermark Medical

Healthcare & Life Sciences

Recent Finacing

Series C

Recent Raise

$30M

Rivermark Medical develops the FloStent™ System, a minimally invasive device for treating Benign Prostatic Hyperplasia (BPH) that aims to restore urinary function while preserving sexual function.

Total Funding

$30M

Headquarters

Milwaukee, USA

Founded

N/A

Website

rivermarkmedical.com

Focus Areas

Benign Prostatic Hyperplasia

minimally invasive device

urinary function

sexual function preservation

clinical development

commercialization.

Investors